JP2005527502A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005527502A5 JP2005527502A5 JP2003569646A JP2003569646A JP2005527502A5 JP 2005527502 A5 JP2005527502 A5 JP 2005527502A5 JP 2003569646 A JP2003569646 A JP 2003569646A JP 2003569646 A JP2003569646 A JP 2003569646A JP 2005527502 A5 JP2005527502 A5 JP 2005527502A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally substituted
- tetrahydrofuran
- diol
- purin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- -1 3-tetrahydrofuranyl Chemical group 0.000 claims 18
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 6
- SSYDTHANSGMJTP-UHFFFAOYSA-N oxolane-3,4-diol Chemical compound OC1COCC1O SSYDTHANSGMJTP-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004545 purin-9-yl group Chemical group N1=CN=C2N(C=NC2=C1)* 0.000 claims 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 229940122614 Adenosine receptor agonist Drugs 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010003662 Atrial flutter Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000003734 Supraventricular Tachycardia Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35796102P | 2002-02-19 | 2002-02-19 | |
| PCT/US2003/007289 WO2003070739A1 (en) | 2002-02-19 | 2003-02-19 | Partial and full agonists of a1 adenosine receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005527502A JP2005527502A (ja) | 2005-09-15 |
| JP2005527502A5 true JP2005527502A5 (https=) | 2006-01-05 |
Family
ID=27757687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003569646A Pending JP2005527502A (ja) | 2002-02-19 | 2003-02-19 | Ａ１アデノシン受容体の部分的および全アゴニスト |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US7144871B2 (https=) |
| EP (2) | EP1476455A1 (https=) |
| JP (1) | JP2005527502A (https=) |
| KR (2) | KR20040084929A (https=) |
| CN (2) | CN1636009A (https=) |
| AU (2) | AU2003223237C1 (https=) |
| CA (1) | CA2476683C (https=) |
| IL (2) | IL163613A0 (https=) |
| MX (1) | MXPA04008008A (https=) |
| NO (1) | NO330243B1 (https=) |
| NZ (1) | NZ534801A (https=) |
| PL (1) | PL372145A1 (https=) |
| RU (1) | RU2317994C2 (https=) |
| WO (1) | WO2003070739A1 (https=) |
| ZA (1) | ZA200406607B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7157440B2 (en) * | 2001-07-13 | 2007-01-02 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| US7713946B2 (en) * | 2002-07-11 | 2010-05-11 | Cv Therapeutics, Inc. | Partial and full agonists A1 adenosine receptors |
| WO2003070739A1 (en) * | 2002-02-19 | 2003-08-28 | Cv Therapeutics, Inc. | Partial and full agonists of a1 adenosine receptors |
| DE102004032651A1 (de) * | 2004-07-06 | 2006-02-16 | Bayer Healthcare Ag | Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen |
| EP1768991A1 (en) * | 2004-07-12 | 2007-04-04 | Cv Therapeutics, Inc. | Process for the preparation of a1-adenosine receptor agonists |
| RU2443708C2 (ru) * | 2007-05-17 | 2012-02-27 | Си Ви Терапьютикс, Инк. | Способ получения агониста рецептора a2a-аденозина и его полиморфных модификаций |
| US20130123345A1 (en) * | 2010-07-23 | 2013-05-16 | The Ohio State University | Method of treating a viral infection dysfunction by disrupting an adenosine receptor pathway |
| JP2015172077A (ja) * | 2015-06-24 | 2015-10-01 | 中国医学科学院葯物研究所 | Ｎ６−置換アデノシン誘導体とｎ６−置換アデニン誘導体の鎮静、催眠、抗うつ、抗痙攣、抗てんかん、抗パーキンソン病と認知証予防・治療の用途 |
| TWI870767B (zh) | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| PE20181894A1 (es) | 2016-03-10 | 2018-12-11 | Janssen Pharmaceutica Nv | Nuevos analogos de nucleosidos sustituidos para su uso como inhibidores de prmt 5 |
| TN2018000310A1 (en) | 2016-03-10 | 2020-01-16 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as prmt5 inhibitors |
| CN109689663B (zh) | 2016-09-14 | 2023-04-14 | 詹森药业有限公司 | Menin-mll相互作用的螺二环抑制剂 |
| MA46228A (fr) | 2016-09-14 | 2019-07-24 | Janssen Pharmaceutica Nv | Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| CN115626935B (zh) | 2016-10-03 | 2025-07-15 | 詹森药业有限公司 | 用作prmt5抑制剂的单环和双环系统取代的卡巴核苷类似物 |
| BR112019012106A2 (pt) | 2016-12-15 | 2019-10-29 | Janssen Pharmaceutica Nv | inibidores de azepano de interação menin-mill |
| EA201990851A1 (ru) | 2017-02-24 | 2019-09-30 | Янссен Фармацевтика Нв | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 |
| CN110382707A (zh) | 2017-02-27 | 2019-10-25 | 詹森药业有限公司 | 生物标志在鉴定将对用prmt5抑制剂治疗有响应的癌症患者中的用途 |
| IL275129B2 (en) | 2017-12-08 | 2023-10-01 | Janssen Pharmaceutica Nv | Novel spirobicyclic analogues |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| RU2020126177A (ru) | 2018-01-09 | 2022-02-10 | Лиганд Фармасьютикалз, Инк. | Ацетальные соединения и их терапевтическое применение |
| WO2020046403A1 (en) * | 2018-08-31 | 2020-03-05 | Muhammed Majeed | Novel process for the preparation of enantiopure 3- enantiopure 3-amino tetrahydrofuran and its salts |
| TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用ｐｒｍｔ５抑制劑治療癌症之方法 |
| JP7598338B2 (ja) | 2019-06-12 | 2024-12-11 | ヤンセン ファーマシューティカ エヌ．ベー． | 新規なスピロ二環式中間体 |
| JP7554829B2 (ja) | 2019-12-19 | 2024-09-20 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換直鎖スピロ誘導体 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5561134A (en) * | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| US5789416B1 (en) | 1996-08-27 | 1999-10-05 | Cv Therapeutics Inc | N6 mono heterocyclic substituted adenosine derivatives |
| GB9813554D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| US6576619B2 (en) * | 1999-05-24 | 2003-06-10 | Cv Therapeutics, Inc. | Orally active A1 adenosine receptor agonists |
| US6294522B1 (en) * | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
| US6258793B1 (en) * | 1999-12-03 | 2001-07-10 | Cv Therapeutics, Inc. | N6 heterocyclic 5′ modified adenosine derivatives |
| US6576620B2 (en) * | 1999-12-03 | 2003-06-10 | Cv Therapeutics, Inc. | Method of identifying partial adenosine A1 receptor agonists |
| US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| GB2372742A (en) * | 2001-03-03 | 2002-09-04 | Univ Leiden | C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses |
| WO2003070739A1 (en) * | 2002-02-19 | 2003-08-28 | Cv Therapeutics, Inc. | Partial and full agonists of a1 adenosine receptors |
-
2003
- 2003-02-19 WO PCT/US2003/007289 patent/WO2003070739A1/en not_active Ceased
- 2003-02-19 AU AU2003223237A patent/AU2003223237C1/en not_active Ceased
- 2003-02-19 CN CNA038041936A patent/CN1636009A/zh active Pending
- 2003-02-19 JP JP2003569646A patent/JP2005527502A/ja active Pending
- 2003-02-19 EP EP03719367A patent/EP1476455A1/en not_active Withdrawn
- 2003-02-19 MX MXPA04008008A patent/MXPA04008008A/es active IP Right Grant
- 2003-02-19 US US10/370,679 patent/US7144871B2/en not_active Expired - Fee Related
- 2003-02-19 EP EP10013734A patent/EP2412716A1/en not_active Withdrawn
- 2003-02-19 CA CA2476683A patent/CA2476683C/en not_active Expired - Fee Related
- 2003-02-19 NZ NZ534801A patent/NZ534801A/en not_active IP Right Cessation
- 2003-02-19 PL PL03372145A patent/PL372145A1/xx not_active Application Discontinuation
- 2003-02-19 KR KR10-2004-7012954A patent/KR20040084929A/ko not_active Ceased
- 2003-02-19 KR KR1020107006113A patent/KR101032005B1/ko not_active Expired - Fee Related
- 2003-02-19 CN CNA2008102118341A patent/CN101392012A/zh active Pending
- 2003-02-19 IL IL16361303A patent/IL163613A0/xx unknown
- 2003-02-19 RU RU2004125492/04A patent/RU2317994C2/ru not_active IP Right Cessation
-
2004
- 2004-08-19 ZA ZA200406607A patent/ZA200406607B/en unknown
- 2004-08-19 IL IL163613A patent/IL163613A/en not_active IP Right Cessation
- 2004-09-17 NO NO20043907A patent/NO330243B1/no not_active IP Right Cessation
-
2006
- 2006-08-24 US US11/510,550 patent/US7696181B2/en not_active Expired - Fee Related
-
2008
- 2008-11-21 AU AU2008249143A patent/AU2008249143B2/en not_active Ceased
-
2009
- 2009-07-23 US US12/508,385 patent/US20090325896A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005527502A5 (https=) | ||
| RU2004125492A (ru) | Частичные и полные агонисты аденозиновых рецепторов а1 | |
| RU2494095C2 (ru) | Модифицированные миметики лизина | |
| US9090603B2 (en) | Compounds for the treatment of proliferative disorders | |
| US20100093717A1 (en) | Triazole compounds that modulate hsp90 activity | |
| JP2015509110A5 (https=) | ||
| JP2015520767A5 (https=) | ||
| RU2009127781A (ru) | Производные аденозина в качестве частичных и полных агонистов а1 аденозиновых рецепторов | |
| JP2017537158A5 (https=) | ||
| JP2005509642A5 (https=) | ||
| RU2013112744A (ru) | Алкил 2-{[(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)-гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино}-пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения | |
| JP2018529671A5 (https=) | ||
| JP2011523952A5 (https=) | ||
| EP3274340B1 (en) | Inhibitors of hepatitis c virus polymerase | |
| JP2006507355A5 (https=) | ||
| CA2662554A1 (en) | Compounds for the treatment of angiogenesis | |
| JP2010530002A5 (https=) | ||
| JP2009501746A5 (https=) | ||
| JP2008511597A5 (https=) | ||
| JP2006516641A5 (https=) | ||
| JPWO2020219650A5 (https=) | ||
| JP2004517151A5 (https=) | ||
| JP2010526051A5 (https=) | ||
| JP2006505525A5 (https=) | ||
| EP4378931A1 (en) | Triazolone compound and medicinal use thereof |